U.S. Stem Cell Stock Forecast, Price & News

U.S. Stem Cell (OTCMKTS:USRM) Frequently Asked Questions

What stocks does MarketBeat like better than U.S. Stem Cell?

Wall Street analysts have given U.S. Stem Cell a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but U.S. Stem Cell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting U.S. Stem Cell?

U.S. Stem Cell saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 60,100 shares, an increase of 84.9% from the August 15th total of 32,500 shares. Based on an average daily volume of 1,156,000 shares, the short-interest ratio is currently 0.1 days.
View U.S. Stem Cell's Short Interest.

When is U.S. Stem Cell's next earnings date?

U.S. Stem Cell is scheduled to release its next quarterly earnings announcement on Friday, July 15th 2022.
View our earnings forecast for U.S. Stem Cell.

How were U.S. Stem Cell's earnings last quarter?

U.S. Stem Cell, Inc. (OTCMKTS:USRM) issued its earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The business earned $1.30 million during the quarter.
View U.S. Stem Cell's earnings history.

How has U.S. Stem Cell's stock price been impacted by Coronavirus?

U.S. Stem Cell's stock was trading at $0.0061 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, USRM stock has increased by 88.5% and is now trading at $0.0115.
View which stocks have been most impacted by COVID-19.

Who are U.S. Stem Cell's key executives?

U.S. Stem Cell's management team includes the following people:

• Miguel Tomás, President, CEO, CFO & Director

Who are some of U.S. Stem Cell's key competitors?

Some companies that are related to U.S. Stem Cell include Vitality Biopharma (VBIO), Protalex (PRTX), DNAPrint Genomics (DNAG), Affinity Energy and Health (ALGXY), Deltagen (DGEN) and Redpoint Bio (RPBC).
View all of USRM's competitors.

What other stocks do shareholders of U.S. Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Stem Cell investors own include Orion Energy Systems (OESX), Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), (APHA), (AQB), Axsome Therapeutics (AXSM) and (BGSF).

What is U.S. Stem Cell's stock symbol?

U.S. Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."

How do I buy shares of U.S. Stem Cell?

Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is U.S. Stem Cell's stock price today?

One share of USRM stock can currently be purchased for approximately $0.01.

How much money does U.S. Stem Cell make?

U.S. Stem Cell has a market capitalization of $5.25 million and generates $280,000.00 in revenue each year.

How many employees does U.S. Stem Cell have?

U.S. Stem Cell employs 11 workers across the globe.

What is U.S. Stem Cell's official website?

The official website for U.S. Stem Cell is www.us-stemcell.com.

Where are U.S. Stem Cell's headquarters?

U.S. Stem Cell is headquartered at 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325.

How can I contact U.S. Stem Cell?

U.S. Stem Cell's mailing address is 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325. The company can be reached via phone at (954) 835-1500 or via email at [email protected].